Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Azer-cel, an allogeneic (allo) CD19 CAR T, in combination with low-dose interleukin-2 (IL-2) demonstrates clinical activity in patients with large B-cell lymphoma (LBCL) who relapsed after autologous (auto) CAR T

View Full Paper
Ask AI
Bookmark
Share

Authors

EWEdmund K. WallerRRRan ReshefVVVinay Vanguru

Discussion

Loading...

Member takes

Overview

Assessment of Azer-cel with low-dose IL-2 reveals 75% overall response in patients with relapsed large B-cell lymphoma, suggesting a new treatment avenue.

Key Points

  • Azer-cel treatment with low-dose IL-2 achieved a 75% overall response rate in relapsed large B-cell lymphoma patients.
  • Complete response rates reached 50%, indicating a significant improvement over previous treatment without IL-2.
  • Observational analysis across 12 patients treated with Azer-cel and low-dose IL-2 yielded important pharmacokinetic data.
  • This study highlights the potential effectiveness of combining azer-cel with IL-2 for patients facing limited treatment options in large B-cell lymphoma.

Cite This Study

Waller et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd3dhttps://doi.org/10.1182/blood-2025-267
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  2. 2Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  3. 3CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  4. 4Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025
  5. 5Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study2025